VisionCare Eye Clinic — Exit Strategy & Investor Returns
Exit pathways — strategic sale, recapitalisation and management buyout — and the indicative investor return analysis over a five-year horizon.
Section 12 · Business Plan
Exit Strategy & Investor Returns
Exit pathways — strategic sale, recapitalisation and management buyout — and the indicative investor return analysis over a five-year horizon.
The promoters recognise that investor capital requires a credible
path to liquidity. Three exit pathways are set out below, each with
specific market evidence from comparable South African transactions.
12.1 Exit Pathway 1 — Strategic Acquisition
Strategic acquisition by a listed hospital group represents the most
probable exit pathway. Netcare Limited, Life Healthcare Group, and
Mediclinic International all operate specialty-clinic portfolios
adjacent to but not replicating the VisionCare model, and have
demonstrated an acquisition appetite for scale, quality, and geographic
reach.
Strategic Acquirer Landscape
| Acquirer | Relevance | Typical EBITDA Multiple | Rationale |
|---|---|---|---|
| Netcare Ltd | Largest private-hospital group; growing day-clinic footprint | 7.0× – 9.0× | Specialty clinic network extension; scheme-network leverage |
| Life Healthcare | Second-largest hospital group with acute-care focus | 6.5× – 8.5× | Diversification into specialist outpatient services |
| Mediclinic International | Listed hospital group with SA core | 6.5× – 8.0× | Adjacency play; integration with existing hospital referral flow |
| Advanced Health / other day-hospital groups | Specialty day-case ownership | 6.0× – 7.5× | Direct consolidation of complementary outpatient operators |
| International strategic (e.g. Vision Group) | Global vision-care platforms with emerging-markets strategies | 7.5× – 10.0× | Emerging-markets platform entry; South Africa as beach-head |
12.2 Exit Pathway 2 — Private Equity Recapitalisation
Several mid-market private equity firms operating in South Africa
have executed specialty-healthcare investments in the past five years. A
recapitalisation at Year 5 by one of these firms — taking a majority
position from the Series A investor while retaining the founder —
represents an alternative to full exit that often produces higher IRR
outcomes for early investors.
Relevant mid-market funds with demonstrated healthcare-sector
interest include: AfricInvest, Ethos Private Equity, Old Mutual Private
Equity, Sanlam Investment Management, and Vantage Capital. Typical deal
structures involve a 50–70% stake acquisition with vendor rollover,
promoter management retention, and a second-stage scale-out plan across
additional metropolitan sites.
12.3 Exit Pathway 3 — Management Buy-Out
As a tail-end option, a management buy-out (MBO) funded from
accumulated retained earnings and new senior debt represents a viable
path for the founder group to reacquire the external equity. By Year 5,
the Company’s distributable cash flow supports senior-debt capacity of
approximately R 30 million, sufficient to retire the Series A equity at
an accretive multiple to the investor.
12.4 Summary of Investor Outcomes Across Exit Scenarios
| Exit Scenario | Timing | Y5 Equity Value | Proceeds to Series A (R M) | Series A IRR |
|---|---|---|---|---|
| Strategic acquisition — conservative | Year 5 | R 85M | R 30.7M | 58.9% |
| Strategic acquisition — median | Year 5 | R 108M | R 39.0M | 67.0% |
| PE recapitalisation | Year 5 | R 95M | R 34.3M | 62.6% |
| Multi-site platform exit | Year 7 | R 165M | R 59.6M | 53.3% |
| MBO at DCF value | Year 5 | R 54M | R 19.5M | 45.5% |
| Downside case exit | Year 6 | R 38M | R 13.7M | 28.6% |
| Alignment of Interests The founder’s substantial equity stake (18.1%) and multi-year operational commitment create strong alignment with Series A investor outcomes. Performance-linked management equity and strict reserved-matter governance ensure that founder control cannot be exercised in ways that compromise investor exit timing or value. The exit window is structured to activate between Year 5 and Year 7 with clear triggering mechanisms — the promoter team has explicit contractual obligations to actively pursue liquidity rather than leaving investors captive. |
Confidential — this business plan is provided to prospective investors and lenders for evaluation purposes only and may not be reproduced or distributed without the written consent of VisionCare Eye Clinic (Pty) Ltd.